FDA vaccine head will step down in April after string of controversial decisions

A key US Food and Drug Administration official who oversees vaccines and biotech remedies will step down from the company following multiple decisions that raised concerns throughout the business.

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will depart the FDA on the finish of April, an company spokesperson confirmed on Friday. It is his second departure from the place: he briefly left the publish in July following backlash over his regulatory decisions, and returned solely two weeks later in August.

In a publish on X, FDA Commissioner Marty Makary mentioned the FDA will appoint a successor earlier than Prasad returns subsequent month to the University of California San Francisco, the place he taught earlier than taking the FDA place final yr. Makary informed Prasad “got a tremendous amount accomplished” throughout his tenure on the company.

Prasad’s determination to step down comes after criticism from the FDA mounted throughout the biotech and pharmaceutical business and amongst former well being officers. In the previous yr, the company has denied or discouraged the approval purposes of at the least eight medication, based on RTW Investments, after taking subject with information the businesses used to help their purposes. The FDA additionally refused to evaluate Moderna’s flu shot earlier than it reversed course.

All of these corporations accused the FDA of reversing earlier steering in regards to the proof they may use to again their purposes, sparking criticism throughout the business that an unreliable regulatory course of may stimulate growth of medication for hard-to-treat ailments.

A former FDA official who spoke to CNBC on the situation of anonymity to talk freely on the problem referred to as the reversals the worst variety of regulatory uncertainty as a result of corporations say they’re being informed one factor after which expertise one other.

In an announcement earlier Friday, an FDA spokesperson mentioned there was “no regulatory uncertainty,” including the company “makes decisions based on the evidence, but does not make assurances about outcomes.” The spokesperson mentioned the FDA is “conducting rigorous, independent reviews and not rubber-stamping approvals.”

The most up-to-date controversy got here after the FDA discouraged UniQure from making use of for expedited approval of its experimental treatment for Huntington’s disease.

The company, which underwent employees cuts and an overhaul beneath Health and Human Services Secretary Robert F. Kennedy Jr., you have faced broader backlash for its medication and approval vaccines course of. Critics have fearful the company may stifle the event of new remedies and danger the protection of sufferers.

The Wall Street Journal earlier reported Prasad’s departure.